Cargando…

Analysis of somatic mutations and key driving factors of cervical cancer progression

We investigated the somatic mutations and key driving factors of cervical cancer by whole exome sequencing . We found 22,183 somatic single nucleotide variations (SNVs) in 52 paired samples. Somatic SNVs in cervical cancer were significantly higher than those in high-grade intraepithelial lesion and...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyazi, Mayinuer, Han, Lili, Husaiyin, Sulaiya, Aishanjiang, Ayimila, Guo, Min, Muhaimati, Gulibanu, Rozi, Hankez, Sun, Haiyan, Lu, Jing, Ma, Chunhua, Rouzi, Nuermangul, Liu, Xiaowan, Zhu, Kaichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390753/
https://www.ncbi.nlm.nih.gov/pubmed/37533736
http://dx.doi.org/10.1515/med-2023-0759
Descripción
Sumario:We investigated the somatic mutations and key driving factors of cervical cancer by whole exome sequencing . We found 22,183 somatic single nucleotide variations (SNVs) in 52 paired samples. Somatic SNVs in cervical cancer were significantly higher than those in high-grade intraepithelial lesion and low-grade squamous intraepithelial lesion groups (P < 0.05). C → T/G accounted for 44.12% of base substitution. Copy number variation (false discovery rate < 0.05) was found in 57 chromosome regions. The three regions with significant differences between cervical cancer and non-cervical cancer groups were 1q21.1, 3q26.33, and 13q33.1, covering genes related to tumor proliferation, differentiation, and apoptosis. The frequency of human papillomavirus (HPV) insertion/integration and the number of “tCw” mutations in the cervical cancer group were significantly higher than those in the non-cervical cancer group (P < 0.05). The total number of mutations was positively correlated with the number of “tCw” mutations (R (2) = 0.7967). HPV insertion/integration (OR = 2.302, CI = 1.523–3.589, P = 0.0005), APOBEC enrichment (OR = 17.875, CI = 2.117–150.937, P = 0.001), and HLA-B*39 in HLA-I (OR = 6.435, CI = 0.823–48.919, P = 0.0042) were risk factors for cervical cancer, while HLA-DQB1*05 in HLA-II was a protective factor (OR = 0.426, CI = 0.197–0.910, P = 0.032). Conclusively, HPV insertion/integration, APOBEC mutagenesis, and HLA polymorphisms are high-risk factors for cervical cancer and may be causes of genome instability and somatic mutations. This study provides experimental data for revealing the molecular mechanism of cervical cancer.